Skip to main content
    P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.48
    +0.02 (+0.05%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Pacira BioSciences, Inc. (PCRX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Pacira BioSciences (PCRX) trades at 20.0x trailing earnings and 2.0x sales. Its P/E of 20.0x is above its 5-year median of 10.9x. Its forward P/E is 9.9x. The median P/E across 11 similar companies is 10.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 102.0% higher over the next year. Its free cash flow yield is 11.6%.

    MultipleValue
    P/E (trailing)20.0x
    Forward P/E9.9x
    Price to sales2.0x
    Price to book2.0x
    EV/EBITDA12.2x
    Price to FCF8.6x
    EV/FCF8.9x
    PEG1.0
    FCF yield11.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 1.5% below 20.3x, its P/S is 53.5% below 4.3x and its P/B is 47.4% below 3.8x.

    MultipleCurrent5-year median10-year median
    P/E20.0x10.9x20.3x
    P/S2.0x1.6x4.3x
    P/B2.0x1.6x3.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 114 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 5.9x in 2024 to 240.3x in 2017.

    Year endPriceP/EP/SP/B
    2025$25.8810.9x1.6x1.6x
    2024$18.845.9x1.3x1.2x
    2023$33.7411.6x2.4x2.0x
    2022$38.6114.9x1.3x2.3x
    2021$60.1720.1x4.9x3.7x
    2020$59.8427.2x6.0x4.3x
    2019$45.3027.1x4.5x5.3x
    2018$43.0241.4x5.3x5.7x
    2017$45.65240.3x6.4x6.8x
    2016$32.3052.1x4.4x5.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PCRX

    What is PCRX's forward P/E ratio?

    Pacira BioSciences has a forward P/E ratio of 9.9x.

    Is PCRX stock overvalued?

    GNG's valuation label for PCRX is Fairly valued. Its P/E of 20.0x compares with a median of 10.7x across 11 similar companies.

    What is PCRX's price to sales ratio?

    Pacira BioSciences has a price to sales ratio of 2.0x.

    What is Pacira BioSciences's average P/E ratio over 5 years?

    Pacira BioSciences's median P/E over the last 5 years is 10.9x, from 60 month-end values through Oct 2026.

    What is PCRX's PEG ratio?

    Pacira BioSciences has a PEG ratio of 1.0.